FDA Webview
X
about-us-banner

FDA Related News

Home / Articles / FDA Related News
latest-news-card-1
Human Drugs

Lupin Gets Warning Letter After Inspection

FDA sends India-based drug maker Lupin a Warning Letter after inspecting its Tarapur, Maharashtra facility 3/22 to 4/4.

latest-news-card-1
Human Drugs

CDER NextGen Portal Taking Certain OTC eSubmissions

FDA expands CDERs NextGen Portal to enable certain electronic over-the-counter monograph submissions under section 505G of the Federal Food, Drug, and...

latest-news-card-1
Human Drugs

Increased Covid Risk For Those on Evusheld: FDA

FDA adds important information to the emergency authorization of AstraZenecas Evusheld to inform health care providers and individuals about the incre...

latest-news-card-1
Human Drugs

Early Reviews of Drug Master Files Cited in ANDAs

FDA posts a draft guidance entitled Review of Drug Master Files in Advance of Certain ANDA Submissions Under GDUFA that introduces an enhancement unde...

latest-news-card-1
Biologics

FDA Funds Biosimilar Research to Boost Development/Review

FDA awards the Biologics & Biosimilars Collective Intelligence Consortium a $1.3 million grant to support biosimilars research and a study focused on ...

Medical Devices

GE Healthcare Gets AIR Recon Imaging Clearance

FDA clears a GE Healthcare 510(k) clearance for its AIR Recon DL for 3D and Propeller imaging sequences for use during magnetic resonance imaging clin...

latest-news-card-1
Human Drugs

BioMarin Refiles BLA for Hemophilia Gene Therapy

BioMarin refiles its BLA for gene therapy valoctocogene roxaparvovec for adults with severe hemophilia A.

Medical Devices

LivaNova Recall of Blood Pump Controller

LivaNova (TandemLife) recalls its LifeSPARC Controller, part of the LifeSPARC blood pump system, due to a software malfunction.

latest-news-card-1
FDA General

User Fee Reauthorization Signed Into Law

A bill, which was attached to a continuing resolution, reauthorizing FDAs user fee programs is signed into law by President Biden.

latest-news-card-1
Human Drugs

1/3 Accelerated Drugs Have Incomplete Confirmatory Trials

An HHS Inspector General data snapshot finds that more than one-third of accelerated drug approvals have delinquent confirmatory trial completions.